Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| S412013-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $99.90 | |
| S412013-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $453.90 | |
| S412013-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,889.90 | |
| S412013-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $3,401.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Secukinumab (anti-IL-17A), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-17A, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | CTLA-8 | Cytotoxic T-lymphocyte-associated antigen 8 | IL-17 | IL-17A |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | IL-17A |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Interleukin 17A inhibitor |
| Product Description | Secukinumab is a human IgG1 Kappa monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis and psoriatic arthritis. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 26.6 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 180.9 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1229022-83-6 |
Secukinumab (anti-IL-17A) (S412013) - ELISA
Immobilized Recombinant Human IL-17A Protein at 1 μg/mL can bind Secukinumab (anti-IL-17A) (S412013) with the EC50 of 69.38 ng/mL.
Secukinumab (anti-IL-17A) (S412013) - SEC
The purity of Secukinumab (anti-IL-17A) (S412013) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| IMGT/mAb-DB | 326 |
|---|---|
| Wikipedia | Secukinumab |
| DrugBank Ligand | DB09029 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0707873 | Certificate of Analysis | Jul 05, 2024 | S412013 |
| ZJ23F0901033 | Certificate of Analysis | Sep 18, 2023 | S412013 |
| ZJ23F0901030 | Certificate of Analysis | Sep 18, 2023 | S412013 |
| 1. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group et al.. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.. Sci Transl Med, 2 (52): (52ra72). [PMID:20926833] |
| 2. Toussirot E. (2012) The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.. Inflamm Allergy Drug Targets, 11 (2): (159-68). [PMID:22280236] |
| 3. van den Berg WB, McInnes IB. (2013) Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.. Semin Arthritis Rheum, 43 (2): (158-70). [PMID:24157091] |
| 4. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T et al.. (2014) One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.. J Rheumatol, 41 (3): (414-21). [PMID:24429175] |
| 5. Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK. (2014) The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.. Glia, 62 (5): (725-35). [PMID:24677511] |
| 6. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B et al.. (2014) Secukinumab in plaque psoriasis--results of two phase 3 trials.. N Engl J Med, 371 (4): (326-38). [PMID:25007392] |
| 7. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M et al.. (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.. N Engl J Med, 373 (26): (2534-48). [PMID:26699169] |
| 8. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup. (2014) Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.. J Dermatol, 41 (12): (1039-46). [PMID:25354738] |
| 9. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB et al.. (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet, 386 (9999): (1137-46). [PMID:26135703] |
| 10. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J et al.. (2015) Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.. N Engl J Med, 373 (14): (1329-39). [PMID:26422723] |
| 11. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] |
| 12. Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM, Collins M et al.. (2008) The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex.. J Immunol, 181 (4): (2799-805). [PMID:18684971] |
| 13. Yao, Z Z and 6 more authors.. (1995) Human IL-17: a novel cytokine derived from T cells.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:7499828] |
| 14. Fossiez, F F and 16 more authors.. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.. The Journal of experimental medicine, (1): [PMID:8676080] |
| 15. Wright, Jill F JF and 12 more authors.. (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells.. The Journal of biological chemistry, (4): [PMID:17355969] |
| 16. Kuestner, Rolf E RE and 27 more authors.. (2007) Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:17911633] |
| 17. Liu, Caini C and 9 more authors.. (2009) Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.. Science signaling, (13): [PMID:19825828] |
| 18. Gerhardt, Stefan S and 22 more authors.. (2009) Structure of IL-17A in complex with a potent, fully human neutralizing antibody.. Journal of molecular biology, (18): [PMID:19835883] |
| 19. Puel, Anne A and 23 more authors.. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.. Science (New York, N.Y.), (1): [PMID:21350122] |
| 20. Liu, Shenping S and 6 more authors.. (2013) Crystal structures of interleukin 17A and its complex with IL-17 receptor A.. Nature communications, [PMID:23695682] |
| 21. Boisson, Bertrand B and 12 more authors.. (2013) An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis.. Immunity, (17): [PMID:24120361] |
| 22. Acharya, Dhiraj D and 11 more authors.. (2017) Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance.. Journal of virology, (1): [PMID:27795421] |
| 23. Goepfert, Arnaud A, Lehmann, Sylvie S, Wirth, Emmanuelle E and Rondeau, Jean-Michel JM.. (2017) The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties.. Scientific reports, (21): [PMID:28827714] |
| 24. Goepfert, Arnaud; Lehmann, Sylvie; Blank, Jutta; Kolbinger, Frank and Rondeau, Jean-Michel.. (2020) Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling.. Immunity, (17): [PMID:32187518] |
